EGFR and cancer: Netarsudil, fedratinib, and osimertinib—specific inhibitors of ROCK1, JAK and EGFR, respectively—are FDA-approved antiproliferative drugs with similar IC50 values in both HeLa and U2OS cells, whereas quercetin and pranlukast do not show any effect on cancer cells viability and proliferation (Supplementary Fig. S2A).